Advances in the development of parvovirus-based anti-cancer therapies

In by

Spotlight Article


Next-Generation Vectors

Dr. Antonio Marchini


Antonio Marchini is a Principal Investigator at the German Cancer Research Center (DKFZ, Heidelberg, Germany) and Head of the Laboratory of Oncolytic Virus Immuno Therapeutics (LOVIT), a newly established joint research unit between the Luxembourg Institute of Health and DKFZ. His team focuses on the development of new anticancer strategies based on oncolytic autonomous parvoviruses (PVs) with the ultimate goal to move them into the clinic. Major areas of research are: i) generation of innovative oncolytic vectors: retargeted PVs, chimeric vectors of adenovirus-PV genomes, PVs expressing sh/miRNAs; ii) design and assessment of novel combination therapies using PVs together with other anticancer agents such as apoptosis inducers, immune checkpoint blockade and/or epigenetic modulators of gene expression. He earned his PhD at the University of Heidelberg in 2001, working on the identification of new cellular proteins interacting with human papillomavirus 16 E7 oncoprotein. Before becoming Principal Investigator, he worked as a Postdoc Scientist at the University of Heidelberg on the characterization of the cellular functions of the SHOX homeodomain protein.

DOI: 10.18609/cgti.2017.016
Citation: Cell Gene Therapy Insights 2017; 3(2),125-130.
Open access

This content is restricted to registered users. Click here to Register or Login here.